McMahon T J, Kadowitz P J
Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
Am J Physiol. 1993 Feb;264(2 Pt 2):H394-402. doi: 10.1152/ajpheart.1993.264.2.H394.
Responses to substance P were investigated in the pulmonary vascular bed of the cat with controlled pulmonary blood flow and constant left atrial pressure. Under baseline conditions, intralobar injections of substance P caused small, inconsistent reductions in lobar arterial pressure (AP) and significant reductions in mean systemic AP without affecting left atrial pressure. Decreases in lobar AP were significant and dose related when lobar vascular resistance was increased with U-46619, a thromboxane A2 mimetic. When compared with other vasodilator agents, the order of potency was substance P approximately bradykinin > pituitary adenylate cyclase activating polypeptide (PACAP) > acetylcholine (in nmol). Pulmonary vasodilator responses to substance P were unchanged by administration of atropine, glibenclamide, or sodium meclofenamate or when airflow to the left lower lung lobe was interrupted by bronchial occlusion. The NO synthesis inhibitor, N omega-nitro-L-argininemethyl ester (L-NAME), and the soluble guanylate cyclase inhibitor, methylene blue (MB), selectively inhibited pulmonary vasodilator responses to substance P and to acetylcholine. MB or L-NAME had no significant effect on pulmonary vasodilator responses to albuterol, lemakalim, or PACAP, whereas MB inhibited and L-NAME enhanced vasodilator responses to NO and sodium nitroprusside. The present investigation demonstrates that, when tone is increased experimentally, substance P has potent pulmonary vasodilator activity, and responses are not dependent on changes in bronchomotor tone, on the activation of muscarinic receptors or ATP-sensitive K+ channels, or on the release of a dilator prostaglandin but do involve, at least in part, endothelium-derived NO release and soluble guanylate cyclase activation.
在肺血流量受控且左心房压力恒定的猫的肺血管床中研究了对P物质的反应。在基线条件下,叶内注射P物质导致叶动脉压(AP)出现小的、不一致的降低,平均体动脉压显著降低,而不影响左心房压力。当用血栓素A2模拟物U-46619增加叶血管阻力时,叶AP的降低显著且与剂量相关。与其他血管扩张剂相比,效力顺序为P物质≈缓激肽>垂体腺苷酸环化酶激活多肽(PACAP)>乙酰胆碱(以nmol计)。给予阿托品、格列本脲或甲氯芬那酸钠,或当左下肺叶气流因支气管阻塞而中断时,肺对P物质的血管扩张反应不变。一氧化氮合成抑制剂Nω-硝基-L-精氨酸甲酯(L-NAME)和可溶性鸟苷酸环化酶抑制剂亚甲蓝(MB)选择性抑制肺对P物质和乙酰胆碱的血管扩张反应。MB或L-NAME对肺对沙丁胺醇、雷马卡林或PACAP的血管扩张反应无显著影响,而MB抑制且L-NAME增强对一氧化氮和硝普钠的血管扩张反应。本研究表明,当通过实验增加张力时,P物质具有强大的肺血管扩张活性,且反应不依赖于支气管运动张力的变化、毒蕈碱受体或ATP敏感性钾通道的激活、舒张性前列腺素的释放,但至少部分涉及内皮源性一氧化氮的释放和可溶性鸟苷酸环化酶的激活。